MedPath

The Role of Chromoendoscopy in the Early Detection of Esophageal Cancer in Patients With Prior Head and Neck Cancers

Not Applicable
Completed
Conditions
Esophageal Squamous Cell Carcinoma
Squamous Cell Carcinoma of the Head and Neck
Interventions
Procedure: NBI endoscopy
Procedure: Lugol chromoendoscopy
Registration Number
NCT02435602
Lead Sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Brief Summary

This study evaluates the role of narrow band imaging (NBI) endoscopy compared with Lugol chromoendoscopy in the early detection of esophageal cancer in patients with prior head and neck cancers.

Detailed Description

Patients with head and neck cancers have an increased risk for developing an esophageal squamous cell carcinoma (ESCC). Small, superficial, curable lesions are difficult to diagnose using only white light endoscopy. To improve detection chromoendoscopy is recommended. In this project patients are divided into two groups based on received chromoendoscopy (NBI versus Lugol). The results of two methods will be compare regarding positive predictive value to establish usage of chromoendoscopy in early detection of ESCC.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
294
Inclusion Criteria
  • Patients with past history ( >= 1 year ) of head and neck cancer treated curatively and receiving regular follow - up at the outpatient clinic of the Head and Neck Department of Maria Skłodowska - Curie Memorial Cancer Center, Institiut of Oncology
  • 18 years and older
  • Diagnosis of squamous cell carcinoma of oral cavity, oropharynx, hypopharynx, larynx
  • Zubrod scale 0-2
  • Provided written informed consent
Exclusion Criteria
  • Lack of written informed consent
  • Known allergy to iodine
  • Clinical conditions precluding upper GI endoscopy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
NBI endoscopyNBI endoscopy* GI endoscopy examination and additional the entire length of esophagus is evaluate with NBI endoscopy * Biopsy at the visually abnormal lesions * Pathologic examination of all biopsy tissue specimens * Advises of endoscopic/surgical or oncological treatment will be given to participants who will be diagnosed with ESCC or high grade dysplasia of the esophagus.
lugol chromoendoscopyLugol chromoendoscopy* GI endoscopy examination and additional the entire length of esophagus is evaluate with Lugol chromoendoscopy * Biopsy at the unstained lesions \>= 5 mm diameter * Pathologic examination of all biopsy tissue specimens * Advises of endoscopic/surgical or oncological treatment will be given to participants who will be diagnosed with ESCC or high grade dysplasia of the esophagus.
Primary Outcome Measures
NameTimeMethod
Positive predictive value2 years

The results of two methods are compare regarding positive predictive value.

Secondary Outcome Measures
NameTimeMethod
Evaluation of endoscopy ( NBI versus Lugol staining) tolerance using Visual Analogue Scale (VAS)2 years
Duration of the esophagoscopy ( NBI versus Lugol staining)2 years

Trial Locations

Locations (1)

Maria Sklodowska-curie Memorial Cancer Center, Institiute of Oncology

🇵🇱

Warsaw, Poland

© Copyright 2025. All Rights Reserved by MedPath